Key Details
Annual Revenue
$2.59 MAnnual EPS
-$0.50Annual ROE
-3521.35%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Nov 14, 2023Recent annual earnings:
Mar 29, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Sept 13, 2006Analyst ratings
Recent major analysts updates
24 Feb '23 Piper Sandler
Neutral16 Nov '22 B. Riley Securities
Neutral23 May '22 Piper Sandler
Overweight31 Mar '22 Truist Securities
Buy30 Mar '22 Piper Sandler
Overweight18 Oct '21 HC Wainwright & Co.
Buy02 Aug '21 JP Morgan
Overweight28 July '21 Wells Fargo
Overweight18 Mar '21 Truist Securities
Buy17 Mar '21 Wells Fargo
Equal-WeightScreeners with INFI included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Infinity Pharmaceuticals doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
Why Is Infinity Pharmaceuticals (INFI) Stock Up 84% Today?
INFI
InvestorPlace08 August 2023
Infinity Pharmaceuticals (NASDAQ: INFI ) stock is rocketing higher on Tuesday morning despite a lack of news from the biopharmaceutical company. Investors seeking out news concerning shares of INFI stock this morning won't find any new press releases or filings.
MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
INFI
Business Wire15 June 2023
SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (“MEI”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced today that the companies will host a recorded joint video webcast that will be available at 8:00 am Eastern.
Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Lags Revenue Estimates
INFI
Zacks Investment Research28 March 2023
Infinity (INFI) delivered earnings and revenue surprises of 8.33% and 95.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Infinity Pharmaceuticals (INFI) Report Negative Q4 Earnings? What You Should Know
INFI
Zacks Investment Research28 March 2023
Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FAQ
- What is the primary business of Infinity Pharmaceuticals?
- What is the ticker symbol for Infinity Pharmaceuticals?
- Does Infinity Pharmaceuticals pay dividends?
- What sector is Infinity Pharmaceuticals in?
- What industry is Infinity Pharmaceuticals in?
- What country is Infinity Pharmaceuticals based in?
- When did Infinity Pharmaceuticals go public?
- Is Infinity Pharmaceuticals in the S&P 500?
- Is Infinity Pharmaceuticals in the NASDAQ 100?
- Is Infinity Pharmaceuticals in the Dow Jones?
- When was Infinity Pharmaceuticals's last earnings report?
- When does Infinity Pharmaceuticals report earnings?
- Should I buy Infinity Pharmaceuticals stock now?
What is the primary business of Infinity Pharmaceuticals?
Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts. On September 29, 2023, Infinity Pharmaceuticals, Inc. along with its affiliate, a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
What is the ticker symbol for Infinity Pharmaceuticals?
The ticker symbol for Infinity Pharmaceuticals is NASDAQ:INFI
Does Infinity Pharmaceuticals pay dividends?
No, Infinity Pharmaceuticals does not pay dividends
What sector is Infinity Pharmaceuticals in?
Infinity Pharmaceuticals is in the Healthcare sector
What industry is Infinity Pharmaceuticals in?
Infinity Pharmaceuticals is in the Biotechnology industry
What country is Infinity Pharmaceuticals based in?
Infinity Pharmaceuticals is headquartered in United States
When did Infinity Pharmaceuticals go public?
Infinity Pharmaceuticals's initial public offering (IPO) was on 28 July 2000
Is Infinity Pharmaceuticals in the S&P 500?
No, Infinity Pharmaceuticals is not included in the S&P 500 index
Is Infinity Pharmaceuticals in the NASDAQ 100?
No, Infinity Pharmaceuticals is not included in the NASDAQ 100 index
Is Infinity Pharmaceuticals in the Dow Jones?
No, Infinity Pharmaceuticals is not included in the Dow Jones index
When was Infinity Pharmaceuticals's last earnings report?
Infinity Pharmaceuticals's most recent earnings report was on 14 November 2023
When does Infinity Pharmaceuticals report earnings?
The date for Infinity Pharmaceuticals's next earnings report has not been announced yet
Should I buy Infinity Pharmaceuticals stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions